Neuroinflammatory perspectives on the two faces of Al'zheimer's disease

Journal of Neural Transmission

Volumn 111, Issue 3, 2004, Pages 281-294

  Eikelenboom, P ^a,b,c   Van Gool, W A ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c Valeriuskliniek ^*  (Netherlands)

Author keywords

amyloid; Acute phase proteins; Alzheimer's disease; Microglia; Neuro inflammation

Indexed keywords

AMYLOID BETA PROTEIN; CELECOXIB; CYTOKINE; HYDROXYCHLOROQUINE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISONE; PROTEIN; ROFECOXIB;

ALZHEIMER DISEASE; AMYLOID NEUROPATHY; AUTOSOMAL DOMINANT DISORDER; CHRONIC INFLAMMATION; EPIDEMIOLOGICAL DATA; HUMAN; IMMUNIZATION; INFLAMMATION; MICROGLIA; NEUROINFLAMMATION; NEURORADIOLOGY; PATHOLOGY; PRIORITY JOURNAL; PROTEIN LOCALIZATION; PROTEIN POLYMORPHISM; REVIEW; SIDE EFFECT; TREATMENT FAILURE;

ACUTE-PHASE REACTION; ALZHEIMER DISEASE; ANIMALS; CHRONIC DISEASE; ENCEPHALITIS; HUMANS;

EID: 1542283611     PISSN: 03009564     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00702-003-0055-1     Document Type: Review

References (75)

1. Abraham CR, Potter H (1989) Alzheimer's disease: recent advances in understanding brain amyloidosis. Biotechnology 7: 147-153
2. Akiyama H, Barker S, Barnum S, Bradt B, Bauer J, Cole GM, Cooper NR, Eikelenboom P, Emmerling M, Fiebich BL et al. (2000) Inflammation and Alzheimer's disease. Neurobiol Aging 21: 383-421
3. Aisen PS, Davis KL, Berg JD, Schafer K, Campell K, Thomas RG, Weiner MF, Farlow MR, Sano M, Grundman M, Thal LJ (2000) A randomized controlled trial of prednisone in Alzheimer's disease. Alzheimer's disease cooperative study. Neurology 54: 588-593
4. Aisen PS, Schafer KA, Grundman M, Pfeiffer E, Sano M, Davis KL, Farlow MR, Jin S, Thomas RG, Thal LJ (2003) Effects of Rofecocib or Naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. JAMA 289: 2819-2826
5. Arends YM, Duyckaerts C, Rozemuller JM, Eikelenboom P, Hauw J-J (2000) Microglia, amyloid and dementia in Alzheimer's disease. A correlative study. Neurobiol Aging 21: 39-47
6. Bagli M, Papassotiropoulos A, Knapp M, Jessen T, Frahnert C, Rao ML, Maier W, Heun R (2000) Association between an interleukin-6 promoter and 3′flanking region haplotype and reduced Alzheimer's risk in a german population. Neurosci Lett 283: 109-112
7. Bales KR, Verina T, Dodel RC, Du YS, Altstiel L, Bender M, Hyslop P, Jonstone EM, Little SP, Cummins DJ, Ricardo P, Ghetti B, Paul SM (1997) Lack of apolipoprotein E dramatically reduces amyloid β-peptide deposition. Nature Genet 17: 263-264
8. Betmouni S, Perry VH, Gordon JL (1996) Evidence for an early inflammatory response in the central nervous system of mice with scrapie. Neuroscience 74: 1-5
9. Bhojak TJ, DeKosky ST, Ganguli M, Kamboh MI (2000) Genetic polymorphisms in the cathepsin G and interleukin-6 genes and the risk of Alzheimer's disease. Neurosci Lett 288: 21-24
10. Blasko I, Marx F, Steiner E, Hartmann T, Grubeck-Loebenstein B (1999) TNFα plus INFγ induce the production of Alzheimer β-amyloid peptides and decrease the secretion of APPs. FASEB J 13: 63-68
11. Blennow K, Wallin A (1992) Clinical heterogenity of probable Alzheimer's disease. J Geriatr Psychiatry Neurol 5: 106-113
12. Cagnin A, Brooks DJ, Kennedy AM, Gunn RN, Myers R, Turkheimer FE, Jones T, Banati RB (2001) In-vivo measurement of microglia in dementia. Lancet 358: 461-467
13. Danton GH, Dietrich WD (2003) Inflammatory mechanisms after ischemia and stroke. J Neuropathol Exp Neurol 62: 127-136
14. Dantzer R, Aubert A, Bluthé RM, Konsman JP, Laye S, Parnet P et al. (2000) Sickness behavior. In: Patterson P, Kordon C, Christen Y (eds) Neuroimmune interactions in neurologic and psychiatric disorders. Springer, Berlin Heidelberg New York Tokyo, pp 169-184
15. De Groot CJ, Hulshof S, Hoozemans JJM, Veerhuis R (2001) Establishment of microglial cell cultures derived from postmortem human adult brain tissue: immunophenotypical and functional characterization. Microsc Res Tech 54: 34-39
16. Dickson DW, Lee SC, Mattiace LA, Yen SC, Brosnan C (1993) Microglia and cytokines in neurological diseases, with special reference to AIDS and Alzheimer's disease. Glia 7: 75-83
17. Dik MG, Pluijm SM, Jonker C, Deeg DJ, Lomeckzy MZ, Lips P (2003) Insulin-like growth factor I (IGF-1) and cognitive decline in older persons. Neurobiol Aging 24: 533-581
18. Dillmann R (1990) Alzheimer's disease. The concept of disease and the construction of medical knowledge. Thesis, Thesis Publishers, Amsterdam
19. Du Y, Dodel RC, Eastwood BJ, Bales KR, Gao F, Lohmuller F, Muller U, Kurz A, Zimmer R, Evans RM et al. (2000) Association of an interleukin 1 alpha polymorphisms with Alzheimer's disease. Neurology 55: 480-483
20. Eikelenboom P, Veerhuis R (1996) The role of complement and activated microglia in the pathogenesis of Alzheimer's disease. Neurobiol Aging 17: 673-680
21. Eikelenboom P, Zhan SS, Van Gool WA, Eikelenboom P (1994) Inflammatory mechanisms in Alzheimer's disease. Trends Pharmacol Sci 15: 147-150
22. Eikelenboom P, Hoogendijk WJG, Jonker C, Van Tilburg W (2002) Immunological mechanisms and the spectrum of psychiatric syndromes in Alzheimer's disease. J Psychiat Res 36: 269-280
23. Engelhart MJ (2002) Inflammation, nutrition and the risk of dementia. The Rotterdam study. Thesis, Erasmus University, Rotterdam
24. Geerlings MI, Schmand B, Braam AW, Jonker C, Bouter LM, Van Tilburg W (2000) Depressive symptoms and risk of Alzheimer's disease in more highly educated older people. J Am Geriatr Soc 48: 1092-1097
25. Gentleman SM, Graham DI, Roberts GW (1993) Molecular pathology of head trauma: Altered beta APP and the aetiology of Alzheimer's disease. Prog Brain Res 96: 237-246
26. Giulian D (1997) Immune responses and Alzheimer's disease. Ann NY Acad Sci 835: 91-110
27. Goldgaber D, Harris HW, Hla T, Maciag T, Donelly RJ, Jacobson JS, Vitek MP, Gajdusek DC (1989) Interleukin-1 regulates synthesis of amyloid β-protein precursor mRNA in human endothelial cells. Proc Natl Acad Sci USA 86: 7606-7610
28. Griffin WSR, Stanley LC, Ling C, White L, MacLeod V, Perrot LJ, White LC, Araoz C (1989) Brain interleukin-1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease. Proc Natl Acad Sci USA 86: 7611-7615
29. Grimaldi LM, Casadei VM, Fern C, Veglia F, Licastro F, Biunno I, De Bellis G, Sorbi S, Mariani C et al. (2000) Association of early-onset Alzheimer's disease with an interleukin-1 alpha gene polymorphism. Ann Neurol 47: 361-365
30. Hofman A, Ott A, Breteler MMB, Bots ML, Slooter AJC, Van Harskamp F, Van Duijn CM, Van Broeckhove C, Van Grobbee DE (1997) Atherosclerosis, apolipoprotein E and the prevalence of dementia and Alzheimer's disease in the Rotterdam study. Lancet 349: 151-154
31. Hoogendijk WJG, Feenstra MGP, Botterblom MH, Gilhuis J, Sommer IEC, Eikelenboom P, Swaab DF (1999) Increased activity of surviving locus coeuleus neurons in Alzheimer's disease. Ann Neurol 45: 82-91
32. Hoozemans JJM, Brückner MK, Rozemuller AJM, Veerhuis R, Eikelenboom P, Arendt T (2002) Cyclin D1 and cyclin E are co-localized with cyclooxygenase-2 in pyramidal neurons in Alzheimer's disease temporal cortex. J Neuropathol Exp Neurol 61: 678-688
33. Hotamisligil GS, Budavari A, Murray D, Spiegelman BN (1994) Reduced tyrosinase kinase activity of the insulin receptor in obesitas-diabetes. Central role of tumour necrosis factor-alpha. J Clin Invest 94: 1543-1549
34. Hoyer S (1998) Is sporadic Alzheimer disease the brain type of non-insulin dependent diabetes mellitus? A challenging hypothesis. J Neural Transm 105: 415-422
35. Hoyer S (2002) The brain insulin signal transduction system and sporadic (type II) Alzheimer disease: an update. J Neural Transm 109: 341-360
36. Huell M, Strauss S, Volk B, Berger M, Bauer J (1995) Interleukin-6 is present in early stages of plaque formation and is restricted to the branis of Alzheimer's disease patients. Acta Neuropathol 89: 544-551
37. In 't Veld BA, Ruitenberg A, Hofman A, Launer LJ, van Duijn CM, Stijnen T, Breteler MMB, Stricker BH (2001) Nonsteroidal antiinflammatory drugs and the risk of Alzheimer's disease. N Engl J Med 345: 1515-1521
38. Jeffrey M, Halliday WG, Bell J, Johnston AR, MacLeod NK, Ingham C, Sayers AR, Brown DA, Fraser JR (2000) Synapse loss associated with abnormal PrP precedes neuronal degeneration in the scrapie-infected murine hippocampus. Neuropathol Appl Neurobiol 26: 41-54
39. Johnson SA, Lamper-Etchells M, Pasinetti GM, Rozovsky I, Finch CE (1992) Complement mRNA in the mammalian brain: responses to Alzheimer's disease and experimental lesioning. Neurobiol Aging 13: 641-648
40. Kalaria RN (1993) The immunopathology of Alzheimer's disease and some related disorders. Brain Pathol 3: 333-347
41. Landreth GE, Heneka MT (2001) Anti-inflammatory actions of peroxisome proliferator-activator receptor gamma agonists in Alzheimer's disease. Neurobiol Aging 22: 937-944
42. Licastro F, Parnetti L, Morini C, Davis J, Cucinotta D, Gaiti A, Senin U (1995) Acute phase reactant alpha 1-antichymotrypsin is increased in cerebrospinal fluid and serum of patients with probable Alzheimer's disease. Alzheimer Dis Assoc Disord 9: 112-118
43. Maes M, DeVos N, Wauters A, Demedts P, Maurits VW, Neels H, Bosmans E, Altamura C, Lin A, Song C, Vandenbroucke M, Sharpe S (1999) Inflammatory markers in younger vs elderly normal volunteers and in patients with Alzheimer's disease. J Psychiat Res 33: 397-405
44. McCusker SM, Curran CD, Dynan KB, McCullagh CD, Urquhart DD, Middleton D, Patterson CC, McIlroy SP, Passmore AP (2001) Association between polymorphism in regulatory region of gene encoding tumour necrosis factor alpha and risk of Alzheimer's disease and vascular dementia: a case-control study. Lancet 357: 436-439
45. McGeer PL, Schultzer M, McGeer EG (1996) Arthritis and anti-inflammatory agents as possible protective factor's for Alzheimer's disease: a review of 17 epidemiological studies. Neurology 47: 425-432
46. Meda L, Cassatella A, Szendrei GI, Otvos L, Baron P, Villaba M, Ferrari D, Rossi F (1995) Activation of microglial cells by β-amyloid protein and interferon-γ. Nature 374: 647-650
47. Molchan SE, Hill JL, Mellow AM, Lawlor BA, Martinez R, Sunderland T (1990) The dexamethasone suppression test in Alzheimer's disease and major depression: relationship to dementia severity, depression and CSF monoamines. Int Psychogeriat 2: 99-122
48. Nandou RD, Scheltens P, Eikelenboom P (2002) Head trauma and Alzheimer's disease. J Alzheimers Dis 4: 303-308
49. Nicoll JA, Mrak RE, Graham DI, Stewart J, Wilcock G, MacGowan S, Esiri MM, Murray LS, Dewar D, Love S et al. (2000) Association of interleukin-1 gene polymorphisms with Alzheimer's disease. Ann Neurol 47: 365-368
50. Nicoll JA, Wikinson D, Holmes C, Steart P, Markham H, Weller R (2003) Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nature Med 9: 448-452
51. Nilsson LNG, Bales KR, DiCarlo G, Gordon MN, Paul SM, Potter H (2001) α-1 Antichymotrypsin promotes β-sheet amyloid plaque formation in a transgenic mouse model of Alzheimer's disease. J Neurochem 21: 1444-1451
52. Potter H (1992) The involvement of astrocytes and an acute phase response in the amyloid deposition of Alzheimer's disease. Prog Brain Res 94: 447-458
53. Perry VH, Newman TA, Cunningham C (2003) The impact of systemic infection on the progression of neurodegenerative disease. Nature Rev Neurosci 4: 103-112
54. Rogers J, Cooper NR, Webster S, Schulz J, McGeer PL, Styren SD, Civin WH, Brachova L, Bradt B, Lieberburg I (1992) Complement activation by β-amyloid in Alzheimer's disease. Proc Natl Acad Sci USA 89: 10016-10020
55. Rogers J, Strohmeyer R, Kovelowski CJ, Li R (2002) Microglia and inflammatory mechanisms in the clearance of amyloid β peptide. Glia 40: 260-269
56. Rozemuller JM, Eikelenboom P, Kamphorst W, Stam FC (1988) Lack of evidence for blood-brain barrier dysfunction in Alzheimer's disease. An immunohistochemical study. Neurobiol Aging 9: 381-388
57. Sainetti SM, Ingram DM, Talwaker S, Geis GS (2000) Results of a double-blind, randomized, placebo-controlled study of celecoxib in the treatment of progression of Alzheimer's disease. Sixth International Stockholm/Springfield symposium on the Advances in Alzheimer Therapy, p 180 (abstract)
58. Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K, Khan K et al. (1999) Immunisation with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 400: 173-177
59. Schmidt R, Schmidt H, Curb JD, Masaki K, White LR, Launer LJ (2002) Early inflammation and dementia: a 25-year follow-up of the Honolulu-asian aging study. Ann Neurol 52: 168-174
60. Selkoe DJ (1999) Translating cell biology into therapeutic advances in Alzheimer's disease. Nature 399: A23-A31
61. Shen Y, Li R, McGeer EG, McGeer PL (1997) Neural expression of mRNAs for complement proteins of the classical pathway in Alzheimer brain. Brain Res 769: 391-395
62. Svennerholm L, Gottfries CG (1994) Membrane lipids, selectively diminished in Alzheimer suggest synapse loss as a primary event in early-onset form (Type I) and demyelination in late-onset form (type II). J Neurochem 62: 1039-1047
63. Van Duijn CM, Hofman A (1990) Risk factors for Alzheimer's disease: The EURODEM collaborative re-analysis of case-control studies. Neuroepidemiology 11: (S1) 106-113
64. Van Gool WA, Eikelenboom P (2000) The two faces of Alzheimer's disease. J Neurol 247: 500-505
65. Van Gool WA, Weinstein HC, Scheltens PK, Walstra GJ (2001) Effect of hydrochloroquine on the progression of dementia in early Alzheimer's disease: an 18-month randomised, double blind, placebo-controlled study. Lancet 358: 455-460
66. Van Gool WA, Aisen PS, Eikelenboom P (2003) Anti-inflammatory therapy in Alzheimer's disease: is hope still alive. J Neurol 250: 788-792
67. Veerhuis R, Janssen I, Hoozemans JJM, De Groot CJA, Hack CE, Eikelenboom P (1998) Complement C1-inhibitor expression in Alzheimer's disease. Acta Neuropathol 96: 287-296
68. Vehmas AK, Kawas CH, Stewart WF, Troncoso JC (2003) Immune reactive cells in senile plaque and cognitive decline in Alzheimer's disease. Neurobiol Aging 24: 321-331
69. Weggen S, Eriksen JL, Das P, Sagi SA, Wang R, Pietrzik CU, Findl KA, Smith TE, Murphy MP, Bulter T, Kang DE, Marquez-Sterling N, Golde TE, Koo EH (2001) A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity. Nature 414: 212-216
70. Williams AE, Van Dam A-M, Eikelenboom P, Fraser H (1997) Immunocytochemical appearance of cytokines, prostaglandin E2 and lipocortin-1 in the CNS during the incubation period of marine scrapie correlates with progressive PrP accumulations. Brain Res 754: 171-180
71. Wyss-Coray T, Mucke L (2002) Inflammation in neurodegenerative disease: a double-edged sword. Neuron 35: 419-432
72. Wyss-Coray T, Yan F, Lin AH, Lambris JD, Alexander JJ, Quigg RJ, Masliah E (2002) Prominent neurodegeneration and increased plaque formation in complement inhibited Alzheimer's mice. Proc Natl Acad Sci USA 99: 10837-10842
73. Yaffe K, Lindquist K, Penninx BW, Simonsick EM, Pahor M, Kritchevsky S, Launer L, Kuller L, Rubin S, Harris T (2003) Inflammatory markers and cognition in well-functioning African-American and white elders. Neurology 61: 76-80
74. Zeidler M, Johnstone EC, Bamber RW, Dickens CM, Fisher CJ, Francis AF, Goldbeck R, Higgo R, Johson-Sabine EC, Lodge GJ et al. (1997) New variant Creutzfeldt-Jacob disease: psychiatric features. Lancet 350: 908-910
75. Zhan SS, Veerhuis R, Kamphorst W, Eikelenboom P (1995) Distribution of beta amyloid associated proteins in plaques in Alzheimer's disease and in non-demented elderly. Neurodegeneration 4: 291-297